Combination photoimmunotherapy and cisplatin: Effects on human ovarian cancer ex vivo

Journal of the National Cancer Institute

Volumn 91, Issue 18, 1999, Pages 1557-1563

  Duska, Linda R ^a   Hamblin, Michael R ^b   Miller, Jaimie L ^b   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OC 125; PHOTOSENSITIZING AGENT; PLATINUM; TALAPORFIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PHOTOTHERAPY; PRIORITY JOURNAL;

EID: 0033568496     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.18.1557     Document Type: Article

References (47)

1. Ozols RF. Treatment of ovarian cancer: current status. Semin Oncol 1994;21(2 Suppl 2):1-9.
2. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90: 889-905.
3. Hasan T, Parrish JA. Photodynamic therapy of cancer. In: Holland JF, Frei EJ III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer medicine. Baltimore (MD): Williams & Wilkins; 1996. p. 739-51.
4. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57.
5. Goff BA, Hermanto U, Rumbaugh J, Blake J, Bamberg M, Hasan T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br J Cancer 1994;70:474-80.
6. Goff BA, Blake J, Bamberg MP, Hasan T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer 1996; 74:1194-8.
7. Mew D, Wat CK, Towers GH, Levy JG. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 1983; 130:1473-7.
8. Oseroff AR, Ohuoha D, Hasan T, Bommer JC, Yarmush ML. Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc Natl Acad Sci U S A 1986; 83:8744-8.
9. Goff BA, Bamberg M, Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res 1991;51:4762-7.
10. Sindelar WF, DeLaney TF, Tochner Z, Thomas GF, Dachoswki LJ, Smith PD, et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. Phase I study. Arch Surg 1991;126:318-24.
11. Hasan T, Lin CW, Lin A. Laser-induced selective cytotoxicity using monoclonal antibody-chromophore conjugates. Prog Clin Biol Res 1989;288:471-7.
12. Hamblin MR, Miller JL, Hasan T. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res 1996;56:5205-10.
13. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
14. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
15. Hosono MN, Endo K, Sakahara H, Watanabe Y, Saga T, Nakai T. et al. Different antigenic nature in apparently healthy women with high serum CA 125 levels compared with typical patients with ovarian cancer. Cancer 1992;70: 2851-6.
16. Duska LR, Hamblin MR, Bamberg MP, Hasan T. Biodistribution of charged F(ab′)2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br J Cancer 1997;75:837-44.
17. Auner H, Petru E, Hofmann HM, Pickel H, Purstner P. In vitro chemosensitivity testing in the treatment of ovarian carcinoma. Arch Gynecol Obstet 1989;246:227-31.
18. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 1994;54:163-70.
19. Federico M, Alberts DS, Garcia DJ, Emerson J, Fanta P, Liu R, et al. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Gynecol Oncol 1994;55(3 Pt 2):S156-63.
20. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47: 331-85.
21. Webb JL. Effect of more than one inhibitor, antagonism, summation, and synergism. Enzyme and metabolic inhibitors. New York (NY): Academic Press: 1963. p. 488-512.
22. Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ Jr, Ozols RF, et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990;45: 416-22.
23. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
24. Sandercock J, Parmar MK. Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 1998;78:1471-8.
25. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994;55(3 Pt 2):S143-50.
26. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 1996;16:16-39.
27. Hamblin MR, Bamberg MP, Miller JL, Hasan T. Cationic photoimmunoconjugates between monoclonal antibodies and hematoporphyrin: selective photodestruction of ovarian cancer cells. Applied Optics 1998;37:7184-92.
28. Leoni F, Bast RC Jr, Canevari S, Menard S, Soper JT, Colnaghi MI. Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer. Int J Cancer 1987;40:592-7.
29. Meier W, Stieber P, Hasholzner U, Gropp M, Fateh-Moghadam A. Prognostic significance of CA125 in patients with ovarian cancer and secondary debulking surgery. Anticancer Res I997;17:2945-7.
30. Eastman A. Characterization of the adducts produced in DNA by cis-diamminedichloro platinum(II) and di-dichloro(ethylenediamine) platinum(II). Biochemistry 1983;22:3927-33.
31. Allday MJ, Inman GJ, Crawford DH, Farrell PJ. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. Embo J 1995;14: 4994-5005.
32. Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55: 1649-54.
33. Los G, Muggia FM. Platinum resistance. Experimental and clinical status. Hematol Oncol Clin North Am 1994;8:411-29.
34. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N. et al. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol 1998;55: 1247-54.
35. Muggia FM, Los G. Platinum resistance: laboratory findings and clinical implications. Stem Cells (Dayt) 1993;11:182-93.
36. Luo Y, Chang CK, Kessel D. Rapid initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1996;63:528-34.
37. Kessel D, Luo Y, Deng Y, Chang CK. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1997;65:422-6.
38. Wood SR, Holroyd JA, Brown SB. The subcellular localization of Zn(II) phthalocyanines and their redistribution on exposure to light. Photochem Photobiol 1997;65:397-402.
39. Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JH. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. Cancer Chemother Pharmacol 1998;41: 186-92.
40. Kessel D, Jeffers R, Fowlkes JB, Cain C. Effects of sonodynamic and photodynamic treatment on cellular thiol levels. J Photochem Photobiol B 1996;32:103-6.
41. Penning LC, Lagerberg JW, VanDierendonck JH, Cornelisse CJ, Dubbelman TM, Van-Steveninck J. The role of DNA damage and inhibition of poly(ADP-ribosyl)ation in loss of clonogenicity of murine L929 fibroblasts, caused by photodynamically induced oxidative stress. Cancer Res 1994;54:5561-7.
42. Ahmad N, Feyes DK, Agarwal R, Mukhtar H. Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. Proc Natl Acad Sci U S A 1998; 95:6977-82.
43. Moorehead RA, Armstrong SG, Wilson BC, Singh G. Cross-resistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy. Cancer Res 1994;54:2556-9.
44. Nahabedian MY, Cohen RA, Contino MF, Terem TM, Wright WH, Berns MW, et al. Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. J Natl Cancer Inst 1988;80:739-43.
45. Canti G, Nicolin A, Cubeddu R, Taroni P, Bandieramonte G, Valentini G. Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors. Cancer Lett 1998;125:39-44.
46. Bolis G, Villa A, Guarnerio P, Ferraris C, Gavoni N, Giardina G, et al. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer 1996;77:128-31.
47. Molpus KL, Koelliker D, Atkins L, Kato DT, Buczek-Thomas J, Fuller AF Jr, et al. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer 1996;68:588-95.